Xeris Biopharma Holdings (XERS) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.06
- Estimate
- $0.03
- Surprise
- +125.0%
- Revenue (period 2026-09-30)
- $107.2M
- Score today
- 5.9/10
Revenue source: xbrl.
How the report landed
Xeris Biopharma Holdings (XERS) beat the $0.03 estimate with adjusted EPS of $0.06 — a large 125.0% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates XERS Sell at 5.9/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's +125.0% surprise compares with a +394.7% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong growth profile
What argues against it
- Concentration risk — Supplier: Regis Technologies
- Concentration risk — Supplier: Lonza Tampa
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $14.40
- Stop
- $13.39
Risk check: RSI 76 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
XERS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $2.38B
- P/E (fwd)
- 66.5
- 52-week range
- $5.25–$13.74
- Off 52-week high
- -4.8%
- RSI (14)
- 76
- Volume vs avg
- 0.99×
- Score today
- 5.9/10